Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAIC Combined With Lenvatinib and PD-1 Inhibitors for Advanced HCC With PVTT
NCT05166239Phase 2Completed
- Sponsor
- Peking University
- Start
- Jan 2022
- Primary completion
- Dec 2023
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of oxaliplatin, fluorouracil in hepatocellular carcinoma (HCC), sponsored by Peking University. Started Jan 2022; status: completed.
02
Drugs
oxaliplatinfluorouracil
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05166239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05166239.